Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Carnaghi, C.
Right arrow Articles by Santoro, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carnaghi, C.
Right arrow Articles by Santoro, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1424-1429, 2002
© 2002 European Society for Medical Oncology

Original Paper

Irinotecan and raltitrexed: an active combination in advanced colorectal cancer

C. Carnaghi, L. Rimassa, I. Garassino, P. A. Zucali, G. Masci, M. Fallini, E. Morenghi and A. Santoro+

Medical Oncology and Haematology Department, Istituto Clinico Humanitas, Milan, Italy

Received 16 November 2001; revised 13 February 2002; accepted 13 March 2002

Background:

Irinotecan and raltitrexed are active agents in metastatic colorectal cancer. Preclinical findings suggest a remarkable synergistic activity between the two drugs and the feasibility of this association has been shown in a recent phase I study. The aim of our phase II trial was to assess the efficacy and tolerability of the combination of irinotecan and raltitrexed in patients with metastatic colorectal cancer untreated with chemotherapy.

Patients and methods:

From June 1998 to February 2000, 46 patients were enrolled. Patients received irinotecan 350 mg/m2 on day 1 and raltitrexed 2.6 mg/m2 on day 2, every 3 weeks, for up to nine courses. Tumour assessment was performed every three cycles.

Results:

A total of 223 cycles of chemotherapy, with a median number of six (range 1–9) courses per patient, was administered. According to intention-to-treat analysis, the overall response rate was 46% (95% confidence interval 31% to 61%). The median duration of response was 21 weeks (range 11–>=101), the median time to progression 27 weeks (range 1–>=116), and the median overall survival 57 weeks (range 1–>=130). The main toxicities were diarrhoea, with National Cancer Institute common toxicity criteria grade 3/4 in 26% of patients, grade 3/4 neutropenia in 20%, grade 3 nausea–vomiting in 13%, grade 3 asthenia in 11% and grade 3/4 transaminase elevation in 4%.

Conclusions:

Results achieved with irinotecan and raltitrexed show that this regimen is active, despite ‘not-negligible’ toxicity, and may represent a useful regimen for specific subgroups of colorectal cancer patients.

Key words: colorectal cancer, irinotecan, metastatic, phase II trial, raltitrexed


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J. Aparicio, J. M. Vicent, I. Maestu, S. Garcera, I. Busquier, C. Bosch, C. Llorca, R. Diaz, C. Fernandez-Martos, and A. Galan
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer
Ann. Onc., July 1, 2003; 14(7): 1121 - 1125.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.